UroGen reports $68.0M ZUSDURI revenue in Q3 2026
FROM THE WIRE · FINANCE.YAHOO.COM
UroGen Pharma Ltd. ZUSDURI® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growth The FDA accepted UroGen's NDA for UGN-103 (next-generation novel mitomycin-based formulation) for review; PDUFA goal date set for June 14…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishZUSDURI revenue grew 35% quarter over quarter, a relevant data point for the UroGen stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01ZUSDURI generated $68.0 million in revenue in Q3 2026.
- 02Quarter-over-quarter growth was 35%.
- 03The FDA accepted the NDA for UGN-103 with a PDUFA date of June 14, 2027.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets